PDF(Pubmed)
Abstract：
Background: SIVA-1 has been reported to play a key role in cell apoptosis and gastric cancer (GC) chemoresistance in vitro. Nevertheless, the clinical significance of SIVA-1 in GC chemotherapy remains unclear. Methods and results: Immunohistochemistry and histoculture drug response assays were used to determine SIVA-1 expression and the inhibition rate (IR) of agents to GC and to further analyze the relationship between these two phenomena. Additionally, cisplatin (DDP)-resistant GC cells were used to elucidate the role and mechanism of SIVA-1 in vivo. The results demonstrated that SIVA-1 expression was positively correlated with the IR of DDP to GC but not with those of 5-fluorouracil (5-FU) or adriamycin (ADM). Furthermore, SIVA-1 overexpression with DDP treatment synergistically inhibited tumor growth in vivo by increasing PCBP1 and decreasing Bcl-2 and Bcl-xL expression. Conclusions: Our study demonstrated that SIVA-1 may serve as an indicator of the GC sensitivity to DDP, and the mechanism of SIVA-1 in GC resistance to DDP was preliminarily revealed.
摘要：
背景：据报道，SIVA-1在体外细胞凋亡和胃癌（GC）化学耐药中起关键作用。然而，SIVA-1在GC化疗中的临床意义尚不清楚.方法和结果：采用免疫组织化学和组织培养药物反应测定SIVA-1的表达和药物对GC的抑制率（IR），并进一步分析这两种现象之间的关系。此外,使用顺铂（DDP）抗性GC细胞阐明SIVA-1在体内的作用和机制。结果表明，SIVA-1的表达与DDP对GC的IR呈正相关，而与5-氟尿嘧啶（5-FU）或阿霉素（ADM）的IR呈正相关。此外，SIVA-1过表达与DDP治疗通过增加PCBP1和降低Bcl-2和Bcl-xL表达在体内协同抑制肿瘤生长。结论：我们的研究表明，SIVA-1可以作为GC对DDP敏感性的指标，初步揭示了SIVA-1对DDP的耐药机制。
